Table 2

Baseline characteristics of biologic-naïve patients by APR levels
Neither APR elevated APR levels discordant Both APR elevated P value
n = 1,012 n = 487 n = 324
Age (years) 60.92 ± 13.49 63.24 ± 13.51 64.26 ± 12.79 <0.0001
Duration of RA (years) 8.62 ± 9.37 9.55 ± 10.46 7.47 ± 8.38 0.0074
One-year follow-up duration (days) 363.43 ± 29.79 364.78 ± 31.48 365.43 ± 31.72 0.5196
mHAQ 0.29 ± 0.38 0.38 ± 0.43 0.48 ± 0.53 <0.0001
CDAI 12.54 ± 10.18 14.61 ± 11.21 19.04 ± 14.91 <0.0001
Tender joints 3.53 ± 5.14 4.10 ± 5.46 5.68 ± 6.92 <0.0001*
Swollen joints 4.19 ± 5.41 4.76 ± 5.53 6.92 ± 6.73 <0.0001*
Patient global assessment 28.47 ± 23.70 34.31 ± 25.08 39.04 ± 27.26 <0.0001
MD global assessment 19.73 ± 15.59 23.22 ± 18.46 31.20 ± 23.03 <0.0001
Prednisone use 247 (24.41%) 138 (28.34%) 124 (38.27%) <0.0001
Methotrexate use 696 (68.77%) 322 (66.12%) 191 (58.95%) 0.0050

*Log-linear model (Poisson) - χ2 test. APR, acute phase reactant; RA, rheumatoid arthritis; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease Activity Index.

Kay et al.

Kay et al. Arthritis Research & Therapy 2014 16:R40   doi:10.1186/ar4469

Open Data